Age and quality of life in patients with rheumatoid arthritis treated with biologic agents.
Nao OguroNobuyuki YajimaYusuke MiwaPublished in: Modern rheumatology (2019)
Objectives: This study aimed to assess the relationship between age and quality of life (QOL) in patients with rheumatoid arthritis (RA) after treatment with biologic agents.Methods: We recruited 153 patients with RA treated with biologic agents at three hospitals of Showa University from 2005 to 2016 for this retrospective cohort study. Patients were divided into two groups-aged 65 years and older (elderly group) and aged under 65 years (adult group). The primary outcome was the change in QOL over 6 months. We measured QOL using the Medical Outcomes Study Short-Form-36 (SF-36), the physical component scale (PCS), and the mental component scale (MCS).Results: There were 94 adult patients (61.4%) and 59 elderly patients (38.5%). Adjusted for sex, disease duration, Disease Activity Score 28 erythrocyte sedimentation rate (DAS28ESR), Health Assessment Questionnaire-Disability Index (HAQ-DI), and complications including interstitial lung disease, diabetes mellitus, and chronic kidney disease, there was a significant difference in PCS changes in 6 months between the groups (regression coefficients -7.25; 95% Confidence Interval (CI) -11.7 to -2.77; p = .0018). There was no significant difference in MCS.Conclusion: Elderly patients with RA may have more difficulty in achieving a satisfactory QOL after treatment with biologic agents.
Keyphrases
- rheumatoid arthritis
- disease activity
- interstitial lung disease
- chronic kidney disease
- end stage renal disease
- ankylosing spondylitis
- rheumatoid arthritis patients
- systemic lupus erythematosus
- healthcare
- mental health
- newly diagnosed
- juvenile idiopathic arthritis
- systemic sclerosis
- physical activity
- middle aged
- community dwelling
- public health
- young adults
- multiple sclerosis
- ejection fraction
- prognostic factors
- escherichia coli
- biofilm formation
- cross sectional
- patient reported outcomes
- pseudomonas aeruginosa
- cystic fibrosis
- patient reported